Minimal Effective Dose of Nomegestrol Acetate Inhibiting the Ovulation in Women Receiving Estradiol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01361958
Recruitment Status : Completed
First Posted : May 27, 2011
Last Update Posted : May 27, 2011
Information provided by:

Brief Summary:

The aim of the present study was to evaluate the ability of several doses of NOMAC in combination with E2 to inhibit ovulation and to assess changes in the gonadotropin and ovarian hormone profiles, in comparison to a control cycle in healthy-volunteer premenopausal women.

The study was also designed to check whether the combined administration of E2 and NOMAC at the dose of 2.5 mg daily induces any changes in the effects of the progestin compared to when it is given alone.

Condition or disease Intervention/treatment Phase
Suppression of Ovulation Drug: NOMAC Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Double-blind, Comparative, Randomized, Single Center, Between-subject, Dose-finding Clinical Trial to Compare 4 Doses of the Combination 17beta-estradiol/Nomegestrol Acetate Administered From Day 1 to Day 21 of the Menstrual Cycle on the Inhibition of Ovulation
Study Start Date : February 1997
Actual Primary Completion Date : November 1997
Actual Study Completion Date : September 1998

Resource links provided by the National Library of Medicine

Drug Information available for: Estradiol
U.S. FDA Resources

Arm Intervention/treatment
Experimental: T1 received 0.625 mg NOMAC + 1.5 mg E2 Drug: NOMAC
Experimental: T2 received 1.25 mg NOMAC + 1.5 mg E2 Drug: NOMAC
Experimental: T3 received 2.5 mg NOMAC + 1.5 mg E2 Drug: NOMAC
Experimental: T4 received 2.5 mg NOMAC + Lactose Drug: NOMAC

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Female premenopausal healthy volunteers having given their informed written consent at the first selection visit,
  • Registered with Social Security in agreement with the French Law on biomedical research on volunteers,
  • Sufficiently co-operative to meet the needs of the study,
  • Accepting not to become pregnant during the trial,
  • Accepting the use of condoms as the single authorized contraceptive means during the trial,
  • With a diurnal and regular job or activity,
  • Aged 18 to 35 years old inclusive,
  • Non-smokers or current smokers of less than 10 cigarettes/day,
  • With normal eating habits,
  • With a body mass index between 17 and 27 inclusive,

Exclusion Criteria:

  • Participation in another clinical trial,
  • Blood donation in the three months prior to Visit V1 or intention to donate blood during the trial or within the three months following the trial completion,
  • Virgins, because of the gynecological examination,
  • Subjects who were within the exclusion period in the Healthy Volunteers National Register of the French Ministry of Health,
  • Forfeiture of freedom by administrative or legal award or under guardianship,
  • No possible contact in case of emergency,
  • Strenuous physical activity planned during the trial. Concerning the gynecological status and examination
  • History of major medical, psychiatric illness or surgery,
  • Any acute or chronic systemic disease or disorder,
  • History of hypersensitivity to at least one drug (abnormal drug reaction or idiosyncrasy or asthma),
  • Abuse of alcohol i.e. history or evidence of acute or chronic abuse, more than 45 g of alcohol per day,
  • Excessive drinking of tea, coffee, chocolate, and/or beverages containing caffeine (>5 cups/day or approximately 500 mg of caffeine per day),
  • Current vascular pathology or with a past history of thrombo-embolic disease, arterial hypertension (BPS ≥ 160 mm Hg or BPD ≥ 95 mm Hg), coronary artery disease, valvulopathy; thrombogenic cardiac rhythm disturbances, cerebrovascular disease, ocular pathology of vascular origin,
  • Cancer or progressive hematological disorder,
  • Current or past history of pituitary tumors,
  • Epilepsy,
  • Known hyperprolactinemia,
  • Known renal insufficiency,
  • Severe or recent liver disease or symptomatic vesicular lithiasis, or recurrent cholestasis or recurring pruritus of pregnancy,
  • Abnormality (> 1N) in liver function on the selection laboratory investigation (ALT or AST > 50 IU/L or alkaline phosphatases > 125 IU/L or total bilirubin > 22 μmol/L or GGT > 70 IU/L),
  • Known diabetes or fasting blood sugar > 6.2 mmol/L (1N) at the selection laboratory investigation,
  • Uncontrolled treated dyslipidemia or cholesterolemia > 5.2 mmol/L (93%N), then > 6.2 mmol/L (110%N) after protocol amendment during the course of the study, or triglyceridemia > 1.80 mmol/L (79 %N) at the selection laboratory investigation,
  • Plasma creatinine > 115 μmol/L (1N),
  • Abnormality in any of the hematology parameters,
  • Positive results at any of the serologies (HBs antigen, HCV antibodies, HIV 1 & 2 antibodies) performed at V1,
  • Positive result for β-HCG at any measurements (i.e. β-HCG > 5 mIU/mL),
  • Abnormality in the baseline EKG,
  • Connective tissue disorder,
  • Porphyria,
  • Otosclerosis,
  • Abnormality at the medical examination performed at V1 which included a neurological examination,
  • Past history or clinical evidence of any malignant tumor or benign disease of the breasts or uterus or ovary (including endometriosis, leiomyomas, polycystic ovaries ...),
  • Vaginal infection at the vaginal bacteriological examination performed at V1. After protocol amendment during the course of the study, infection diagnosed at the vaginal bacteriology or at the cervico-vaginal smear was removed from the exclusion criteria list.
  • Hysterectomy, even partial, or endometrectomy,
  • Pregnancy,
  • Childbirth, breast-feeding, miscarriage or termination of pregnancy in the year prior to V1,

Responsible Party: Dr Didier Chassard, Aster, Paris, France Identifier: NCT01361958     History of Changes
Other Study ID Numbers: 96-ESC/NOM-1-RD
First Posted: May 27, 2011    Key Record Dates
Last Update Posted: May 27, 2011
Last Verified: May 2011

Additional relevant MeSH terms:
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs